Long-term curative effect of tacrolimus in kidney transplantation patients in China:Meta-analysis

Zhan Sheng-li,Cai Ming,Shi Bing-yi,Li Zhou-li,Li Peng-cheng,Li Cong-ran,Liang Tao,Liu Chang
DOI: https://doi.org/10.3969/j.issn.1673-8225.2009.53.003
2009-01-01
Abstract:OBJECTIVE:Tacrolimus is widely used in organ transplant.However,the long-term effects of tacrolimus on Asian,in particular in Chinese people,are few.The aim of this study is to evaluate the efficacy and safety of long-term curative effect of tacrolimus used in kidney transplantation patients in China.DATA SOURCES:Electronic and manual retrieve of Medline database,Chinese journal full-text database,Cochrane library,and CEBM/CCD,and relevant medical journals in China were applied.DATA SELECTION:Published randomized controlled trials on tacrolimus in kidney allograft recipient were retrieved,and the data were underwent Meta analysis.Odds ratio (OR) and its 95% confidence interval (CI) were used as the measurement parameter of efficacy comparison.The statistical analyses were performed using Stata software.MAIN OUTCOME MEASURES:① The survival ratio of patient/kidney after 1 year.②The survival ratio of patient/kidney after 3 years.③ Rejection ratio after 3 years.④ Infection rate after 3 years.⑤ Incidence of liver dysfunction after 3 years.⑥Blood glucose disorder after 3 years.RESULTS:A total of 3 trials were eligible for the inclusion efficacy,including 3 Chinese trials and 0 foreign trials.Results of meta-analysis indicated that tacrolimus prevented the recipients of kidney transplantation from rejection effectively in three years [OR=0.40,95%CI (0.27-0.61),P < 0.000 1].Tacrolimus prevented the recipients of kidney transplantation from impaired liver function in three years [OR=0.28,95%CI (0.15-0.52),P < 0.000 1].No statistical difference of the 1-year and 3-year survival rate of patients/kidney was found in the patients between group tacrolimus and group cyclosporine.Statistical difference of blood glucose disorder were found in the patients between group tacrolimus and group cyclosporine [OR=2.39,95%CI (1.41-4.05),P=0.001].CONCLUSIONS:Tacrolimus prevented the recipients of kidney transplantation from rejection and impaired liver function effectively in three years in China.No statistical difference of the 1-year and 3-year survival rate of patients/kidney was found in the patients between two groups.In addition,the main side effect of tacrolimus is blood glucose elevation.
What problem does this paper attempt to address?